EP1007042A4 - Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine - Google Patents

Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine

Info

Publication number
EP1007042A4
EP1007042A4 EP98929059A EP98929059A EP1007042A4 EP 1007042 A4 EP1007042 A4 EP 1007042A4 EP 98929059 A EP98929059 A EP 98929059A EP 98929059 A EP98929059 A EP 98929059A EP 1007042 A4 EP1007042 A4 EP 1007042A4
Authority
EP
European Patent Office
Prior art keywords
modulation
signal transduction
protein tyrosine
cellular signal
heteroaryl compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98929059A
Other languages
German (de)
English (en)
Other versions
EP1007042A1 (fr
Inventor
Peng Cho Tang
Gerald Mcmahon
John Y Ramphal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of EP1007042A1 publication Critical patent/EP1007042A1/fr
Publication of EP1007042A4 publication Critical patent/EP1007042A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP98929059A 1997-06-13 1998-06-12 Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine Withdrawn EP1007042A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4956097P 1997-06-13 1997-06-13
US49560P 1997-06-13
PCT/US1998/012333 WO1998056376A1 (fr) 1997-06-13 1998-06-12 Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine

Publications (2)

Publication Number Publication Date
EP1007042A1 EP1007042A1 (fr) 2000-06-14
EP1007042A4 true EP1007042A4 (fr) 2001-07-04

Family

ID=21960475

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98929059A Withdrawn EP1007042A4 (fr) 1997-06-13 1998-06-12 Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine

Country Status (5)

Country Link
EP (1) EP1007042A4 (fr)
JP (1) JP2002512628A (fr)
AU (1) AU8071698A (fr)
CA (1) CA2293400A1 (fr)
WO (1) WO1998056376A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
JP2002507598A (ja) * 1998-03-26 2002-03-12 スージェン・インコーポレーテッド チロシン蛋白質キナーゼを調節するためのヘテロ環式化合物のファミリー
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
IL139934A0 (en) 1998-05-29 2002-02-10 Sugen Inc Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2382789A1 (fr) 1999-08-27 2001-03-08 Sugen, Inc. Mimetiques phosphates et procedes de traitement utilisant des inhibiteurs de phosphatase
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
AR034118A1 (es) 2000-02-15 2004-02-04 Sugen Inc Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US6933303B2 (en) 2001-10-19 2005-08-23 Transtech Pharma, Inc. Heteroaryl-fused nitrogen heterocycles as therapeutic agents
CA2468184A1 (fr) * 2001-11-28 2003-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R A.S.) Derives de 5-sulfanyl-4h-1,2,4-triazoles et leur utilisation en tant que medicament
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
AR047894A1 (es) 2004-02-25 2006-03-01 Wyeth Corp Derivados de tiofeno como inhibidores de la proteina tirosina fosfatasa 1b (ptpasa 1b); metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por ptpasa 1b
US10894784B2 (en) 2015-12-18 2021-01-19 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (fr) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Composés hétéroarylbenzimidazole substitués
PH12019500056B1 (en) * 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
TW201831478A (zh) 2016-12-02 2018-09-01 瑞士商赫孚孟拉羅股份公司 雙環醯胺化合物及其使用方法
SG11201906412SA (en) * 2017-01-23 2019-08-27 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors
BR112019015075A2 (pt) 2017-01-23 2020-03-10 Revolution Medicines, Inc. Compostos bicíclicos como inibidores de shp2 alostéricos
MA49560B1 (fr) 2017-07-14 2024-05-31 Hoffmann La Roche Composés cétoniques bicycliques et leurs procédés d'utilisation
JP7356414B2 (ja) 2017-09-07 2023-10-04 レヴォリューション・メディスンズ，インコーポレイテッド がんを治療するためのｓｈｐ２阻害剤組成物および方法
CR20200151A (es) 2017-10-11 2020-05-23 Hoffmann La Roche Compuestos bicíclicos y métodos de utilización de los mismos
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
SG11202002877RA (en) * 2017-10-31 2020-04-29 Hoffmann La Roche Bicyclic sulfones and sulfoxides and methods of use thereof
CA3084058A1 (fr) 2017-12-15 2019-06-20 Revolution Medicines, Inc. Composes polycycliques utilises en tant qu'inhibiteurs allosteriques de shp2
CN118978535A (zh) 2018-05-01 2024-11-19 锐新医药公司 作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物
CN113302193A (zh) 2019-01-11 2021-08-24 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
AU2021342568B2 (en) 2020-09-21 2025-04-03 Landos Biopharma, Inc. Nlrx1 ligands
CN120004879B (zh) * 2025-02-14 2026-04-07 中国药科大学 一类含有硫醚骨架结构的化合物及其在制备磷酸甘油酸脱氢酶抑制剂中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602851A1 (fr) * 1992-12-10 1994-06-22 Zeneca Limited Dérivés de Quinazoline
WO1997003069A1 (fr) * 1995-07-13 1997-01-30 Glaxo Group Limited Composes heterocycliques et compositions pharmaceutiques a base desdits composes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798374A (en) * 1995-06-07 1998-08-25 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602851A1 (fr) * 1992-12-10 1994-06-22 Zeneca Limited Dérivés de Quinazoline
WO1997003069A1 (fr) * 1995-07-13 1997-01-30 Glaxo Group Limited Composes heterocycliques et compositions pharmaceutiques a base desdits composes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Foerderung der Chemischen Wissenschaften, FRANKFURT/MAIN, DE; XP002166113, Database accession no. 4752105 (BRN) *
IZV. AKAD. NAUK SSSR SER. KHIM., vol. 6, 1990, pages 1392 - 1397 *
LAGORCE JF: "Synthèse et activité antithyroïdienne de dérivés du triazole", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY - CHIMIA THERAPEUTICA, vol. 27, no. 4, 1992, pages 359 - 368, XP002166110 *
See also references of WO9856376A1 *
SHAW J T ET AL: "The preparation of some 2,6-diaminopy", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 17, January 1980 (1980-01-01), pages 11 - 16, XP002166112 *
THORNBER C W ET AL: "A three component cyclisation of 2-cyanamido-4,6-dimethyl pyrimidines with aldehydes and amines", SYNTHESIS, no. 3, March 1983 (1983-03-01), pages 222 - 223, XP002166111 *

Also Published As

Publication number Publication date
WO1998056376A1 (fr) 1998-12-17
AU8071698A (en) 1998-12-30
CA2293400A1 (fr) 1998-12-17
EP1007042A1 (fr) 2000-06-14
JP2002512628A (ja) 2002-04-23

Similar Documents

Publication Publication Date Title
AU8071698A (en) Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
AU2804597A (en) Synthesis of fluorophore-labeled dna
AU3363599A (en) Heterocyclic families of compounds for the modulation of tyrosine protein kinase
AU5468499A (en) 3-methylidenyl-2-indolinone modulators of protein kinase
AU3766897A (en) Fused heterocyclic compounds as protein tyrosine kinase inhibitors
AU1529997A (en) Substituted histidine inhibitors of protein farnesyltransferase
AU6411698A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
AU8586298A (en) Designed protein pores as components for biosensors
AU3693697A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU3443997A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU2805897A (en) Inhibitors of protein farnesyltransferase
AU1371999A (en) Benzothiazole protein tyrosine kinase inhibitors
PL339738A1 (en) Novel lactamic inhibitors of metaloproteinases
AU8589798A (en) Selective synthesis of organodiphosphite compounds
AU2713699A (en) Modulators of protein tyrosine phosphatases (ptpases)
AU1381499A (en) Cell-permeable protein inhibitors of calpain
IL132170A0 (en) Novel heterocyclic compounds
ZA983065B (en) Inhibitors of protein farnesyltranferase
DE69826878D1 (de) Wiederkodierung von dekodierten signalen
DE60040524D1 (de) Intein-vermittelte ligation von exprimierten proteinen
AU1599299A (en) Methods and reagents for the utilization of sap family member proteins, novel signal transduction regulators
AU2766999A (en) Synthesis of chiral beta-amino acids
AU6275098A (en) Novel h-rev 107-like protein
AU4684099A (en) Oligonucleotides for enhanced modulation of protein kinase expression
AU1621400A (en) Novel phosphodiesterase interacting proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 403/12 A, 7C 07D 409/14 B, 7A 61K 31/495 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010523

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010816